1. Introduction {#sec1}
===============

Patients with rheumatoid arthritis (RA) have 2-5 times increased the risk of premature cardiovascular disease (CVD), which shortens their life expectancy by 5-10 years \[[@B1]\]. Many studies have emerged between the paradigm of inflammation in the pathogenesis of atherosclerosis and the well-established mechanisms of inflammation in the pathogenesis of RA \[[@B1], [@B2]\]. Common proinflammatory cytokines are involved in the development and progression of both RA and atherosclerosis. Proinflammatory cytokines, such as interleukin- (IL-) 1, IL-6, and tumor necrosis factor-alpha (TNF-*α*), produced within locally affected joints in RA may promote both traditional \[e.g., dyslipidemia and insulin resistance (IR)\] and nontraditional (e.g., oxidative stress) systemic cardiovascular risk factors \[[@B2]\].

A study reported that RA patients have a significantly higher risk of coronary heart disease than do non-RA patients. RA patients are less likely to report symptoms of angina and more likely to experience unrecognized myocardial infarction (MI) and sudden cardiac death \[[@B3]\]. Another population-based study indicated that congestive heart failure (CHF) incidence rates were 1.99 and 1.16 cases per 100 person-years in RA and non-RA patients, respectively \[[@B4]\].

Because inflammation plays crucial roles in RA and CVD as well as in the increased cardiovascular risk in RA, the suppression of inflammation can ultimately lower the cardiovascular morbidity and mortality in RA patients \[[@B5]\]. Antirheumatic drugs include glucocorticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), disease-modifying antirheumatic drugs (DMARDs), and biological agents (e.g., anti-TNF-*α* therapy). In inflammatory disorders, the suppression of systemic inflammation favoring atherosclerosis may lead to an improvement in cardiovascular prognosis. In RA, the attenuation of inflammatory joint disease through the administration of anti-TNF-*α* therapy, or probably any powerful disease-modifying antirheumatic drug, is associated with a concomitant reduction in the risk of cardiovascular events \[[@B6]\].

Patients with RA may have a higher risk of CVD; understanding the relationship between these conditions is important for clinicians. This retrospective cohort study was conducted to investigate the prescribing trend of antirheumatic drugs and assess the risk of CVD in patients with RA by using nationwide data from the National Health Insurance Research Database (NHIRD) in Taiwan.

2. Materials and Methods {#sec2}
========================

2.1. Data Source {#sec2.1}
----------------

This nationwide retrospective cohort study was based on the data from Longitudinal Health Insurance Database (LHID), which was randomly selected from the NHIRD provided by the National Health Insurance Administration, Ministry of Health and Welfare, and managed by National Health Research Institutes (Registered number NHIRD-104-004). The LHID comprises the data of detailed clinical records from patient visits, primary and secondary diagnostic codes, and prescription orders for one million randomly selected beneficiaries of the National Health Insurance (NHI) program. The NHI program of Taiwan has been launched since 1995 and \>99% of citizens are all enrolled in the program. Therefore, the NHIRD can represent the utilization conditions of medical resources for the 23 million residents and is one of the largest databases universally. This study was exempted from informed consent because the personal identification data were encrypted and transformed in the NHIRD. This study protocol was approved by the Institutional Review Board of China Medical University and Hospital, Taiwan (IRB No.: CMUH103-REC-002).

2.2. Study Subjects {#sec2.2}
-------------------

The case group in the study was patients with new diagnosis RA. The definition of RA patients was RA diagnosis three times a year, according to the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) code 714 and receiving at least one of these drugs (i.e., steroids, NSAIDs, or DMARDs). We excluded patients who received CVD diagnosis before RA to reduce the study bias. Furthermore, we used the propensity score matching (PSM) to obtain general patients, in 1:5 matching for each RA patient, as the control group. The general patients who we selected for the control group had not received any RA diagnosis during the study period. The propensity score is the probability that a unit with certain characteristics will be assigned to RA patients. The scores could be used to reduce or eliminate selection bias in observational studies by the characteristics of RA patients and general patients. The characteristics we selected for matching were gender, age, premium-based monthly income, and urbanization.

2.3. Study Designs {#sec2.3}
------------------

This study was conducted using 2002-2013 claim data from LHID. We enrolled RA patients and general patients from 2003-2010 as the study subject, to ensure that exclusion condition and each patient had at least 3 years of follow-up. [Figure 1](#fig1){ref-type="fig"} lists flowchart of selection patients for inclusion. We enrolled 15,366 RA patients and 76,830 general patients between 2003 and 2010. Each patient was follow-up until the date of incident CVD, death, or the end of 2013, whichever occurred first. We calculated the prescriptions of antirheumatic drugs during the study period and estimated the risk of CVD in RA patients. The definition of CVD in the study contained acute myocardial infarction (MI) (ICD-9-CM code 410), angina pectoris (ICD-9-CM code 413), congestive heart failure (CHF) (ICD-9-CM code 428.0), left heart failure (ICD-9-CM code 428.1), and heart failure, unspecified (ICD-9-CM code 428.9).

The study used the Cox proportional hazard model to estimate the hazard ratios with 95% confidence interval (CI) for the association between RA and CVD, after controlling for related variables. Control variables were sex, age, and comorbidity diseases. The comorbidity disease contained hypertension (HTN) (ICD-9-CM codes 401-405), hyperlipidemia (HPL) (ICD-9-CM code 272), metabolic syndrome (MS) (ICD-9-CM code 277), diabetes mellitus (DM) (ICD-9-CM code 250), and chronic kidney disease (CKD) (ICD-9-CM codes 580-588).

All statistical analyses in the study were using SAS software version 9.4 (SAS Institute Inc., Cary, NC, USA) and SPSS version 18 (IBM SPSS Inc., Chicago, IL, USA). Statistical significance in this study was defined as p \< 0.05.

3. Results {#sec3}
==========

3.1. The Characteristic Distribution of Study Subject after Matching {#sec3.1}
--------------------------------------------------------------------

[Table 1](#tab1){ref-type="table"} lists the basic characteristics of RA patients and general patients after matching. A total of 92,196 patients aged \>34 years were selected from a nationally representative sample of Taiwan\'s LHID from 2003 to 2010. Among them, 15,366 and 76,830 were RA patients and general patients, respectively; 68.09% were women and 31.91% were men. The average age of RA patients was 50.01 years and standard deviation (SD) was 16.02 years; the age of general patients was 49.26 ± 17.07 years. As expected, the characteristics distribution of RA and general patients was no significant differences after matching.

3.2. The Prescribing Trend of Antirheumatic Drugs {#sec3.2}
-------------------------------------------------

[Figure 2](#fig2){ref-type="fig"} showed the prescribing trend of antirheumatic drugs from 2003 to 2010. NSAIDs were the most commonly used drug since 2003 (11,015 prescriptions in 2003 to 15,865 prescriptions in 2010). In addition, DMARDs increased over two times from 2003 to 2010 (7,225 prescriptions in 2003 and 14,150 prescriptions in 2010). Steroids were only 6,060 prescriptions in 2003 and rose to 11,169 prescriptions in 2010.

3.3. The Risk of CVD in RA Patients {#sec3.3}
-----------------------------------

As [Table 2](#tab2){ref-type="table"}, among the 92,196 participants, 6,665 patients (7.23%) had CVD. A higher percentage of RA patients had CVD than general patients (8.56% versus 6.96%). The cumulative risk of CVD was significantly higher in RA patients than in general patients ([Figure 3](#fig3){ref-type="fig"}; Log-rank test, p-value \< 0.001). The age of patients with CVD was 64.85 ± 12.43 years; the age of patients without CVD was 48.19 ± 16.60 years. The patients with HTN had a higher percentage on incident CVD, compared with the patients without HTN (13.18% versus 6.60%). The patients with other comorbidity disease also had a higher percentage on incident CVD, compared with the patients without comorbidity disease (HPL: 14.79% versus 7.20%; MS: 10.22% versus 7.22%; DM: 18.01% versus 6.33%; CKD: 18.84% versus 7.03%). In addition, the distribution of the most covariates associated with CVD was statistically significant difference, except MS.

[Table 3](#tab3){ref-type="table"} shows the hazard ratios (HR) for CVD among RA patients and general patients. The average follow-up time was 5.04 years in RA patients and 5.60 years in general patients, respectively. After controlling for other relevant influencing factors, RA patients had a higher risk being adjusted HR of 1.31 (95% CI: 1.23-1.39) than general patients. Compared with patients without HTN, the adjusted HR was 1.57 (95% CI: 1.48-1.65) in those with HTN. Compared with patients without DM, the adjusted HR was 1.47 (95% CI: 1.38-1.57) in those with DM. Compared with patients without CKD, the adjusted HR was 1.48 (95% CI: 1.31-1.66) in those with CKD. Furthermore, the age was the greatest risk factors contributing to the occurrence of incident CVD. The risk of CVD was higher in elderly patients than in those aged ≦34 years; the adjusted HR was 17.65 (95% CI: 13.97-22.31) in 55-64-year-old patients and 40.32 (95% CI: 31.99-50.84) in ≥65-year-old patients.

4. Discussion {#sec4}
=============

The study results demonstrated that RA patients had a higher risk of CVD than general patients. Patients with comorbidities contained HTN, DM, and CKD increased the risk of CVD. In addition, study results also provided evidence that elderly patients were at a higher risk of CVD than the patients aged less than 34 years.

RA is associated with an increased burden of CVD, which is at least partially attributed to classical risk factors such as HTN and dyslipidemia \[[@B7], [@B8]\]. HTN is one of the most important modifiable risk factors for CVD in the general population \[[@B9]\] and is more common in patients with RA. HTN in patients with RA is associated with increasing concentrations of homocysteine and leptin. The pathogenesis of HTN in RA may involve pathways more regularly associated with fat and vascular homeostasis \[[@B10]\]. RA patients with higher erythrocyte sedimentation rates and the presence of extra-articular manifestations were more likely to exhibit dyslipidemia \[[@B11]\]. The prevalence of dyslipidemia in Japanese patients with RA is higher than that in the non-RA population. Controlling RA disease activity might improve lipid profiles and lower CVD risk. A low dose of atorvastatin was effective for the treatment of dyslipidemia in RA patients but had no apparent effect on RA disease activity \[[@B12]\]. In our study, HTN was a risk factor for CVD in patients with RA. This result is similar to that of other studies.

Patients with RA have characteristics that indicate a high risk of type 2 DM. Controlling inflammation may improve insulin sensitivity and subsequently reduce the risk of type 2 DM in RA patients. This may also reduce the risk of CVD in high-risk groups \[[@B13]\]. One study indicated that RA is apparently associated with an increased risk of type 2 DM in Taiwan. Compared with non-RA, the OR of RA for type 2 DM was 1.68 (95% CI: 1.53-1.84) in men and 1.46 (95% CI: 1.39-1.54) in women \[[@B14]\]. In our study, DM was identified as a risk factor for CVD, which is similar to the results of previous studies. A systematic review and meta-analysis indicated that HTN, type 2 DM, smoking, hypercholesterolemia, and obesity increased CVD risk in patients with RA \[[@B15]\].

Renal disease in RA is clinically important. The previous study demonstrated that RA patients are more prone to have CKD. This could have serious implications, as the majority of RA patients use NSAIDs and different immunosuppressive drugs \[[@B16]\]. Another study indicated that the strong association between mild CKD and CVD has been shown and reported that end-stage renal disease (ESRD) is strongly associated with an increase in CVD mortality \[[@B17], [@B18]\]. In our study, CKD was a risk factor for CVD in patients with RA, which is consistent with the results of previous studies.

We also identified that the risk of CVD was higher in elderly patients with RA. Accelerated aging caused by the senescence of multiple systems represents an attractive biological model that may partly explain the increase in CVD and mortality rates observed in RA \[[@B19]\]. One study indicated that age exerts an exponentially increasing effect on CVD risk in seropositive RA but no increased effect among seronegative patients. The effect of age on CVD risk in seropositive RA was nearly double its effect on the general population, with additional log (age) coefficients of 2.91 for women (p = 0.002) and 2.06 for men (p = 0.027) \[[@B20]\]. This finding is similar to that of our study.

Antirheumatic drugs include glucocorticosteroids, NSAIDs, DMARDs, and biological agents. NSAIDs and oral glucocorticosteroids likely contribute to the increased CVD risk in RA \[[@B21]\]. A recent meta-analysis suggested that all NSAIDs confer some CVD risk. The CVD risks or benefits associated with the use of DMARDs and/or biological agents as well as the role of statins in RA remain controversial \[[@B22]\].

As the study results, the proportion of NSAID prescriptions was highest from 2003 to 2010 in Taiwan. Nonselective NSAIDs and coxibs are commonly used in RA, and their effects on renal function and blood pressure should be considered, especially in patients with preexisting HTN or renal impairment and in elderly patients with the most pronounced side effects \[[@B23]\]. One study revealed that MI in RA is associated with demographic and cardiovascular risk factors and corticosteroid use. The covariate-adjusted risk of first MI in RA versus that in noninflammatory rheumatic disorders was 1.9 (95% CI: 1.2-2.9, p = 0.005). The use of corticosteroids was associated with the future development of DM and HTN \[[@B24]\]. Patients treated with high-dose steroids (\>7.5 mg/day of prednisone) appear to have twice the risk of heart disease compared with those not treated with steroids \[[@B25]\].

Because of their robust disease-modifying effects on both proinflammatory and proatherogenic pathways, biological treatments have been substantially speculated to serve as a highly effective RA disease control \[[@B26]\]. Methotrexate (MTX) is considered the first-line DMARD agent for RA. One study reported that MTX use is associated with a reduced risk of CVD events in patients with RA. In RA, the reduction of inflammation through MTX use not only improves disease-specific outcomes but may also reduce collateral damage such as atherosclerosis \[[@B27]\]. Rheumatoid factor positivity and erosions both increased CVD risk, with ORs of 2.04 (1.02-4.07) and 2.36 (0.92-6.08), respectively. MTX and, to a lesser extent, sulfasalazine were associated with a significantly lower CVD risk than that in RA patients who never used sulfasalazine, hydroxychloroquine, or MTX. DMARD use, in particular MTX use, results in the powerful suppression of inflammation, thereby reducing the development of atherosclerosis and subsequently clinically overt CVD \[[@B28]\].

Anti-TNF-*α* therapy is associated with a significantly increased risk of HTN in patients with RA. Physicians should be aware of this risk and provide continual monitoring in patients receiving these therapies \[[@B29]\]. Type 2 DM is associated with IR, which is partially caused by TNF-*α*, a major effecter of IR in humans with type 2 DM. Anti-TNF-*α* therapy for autoimmune diseases resulted in a significant improvement in the fasting blood glucose, glycated hemoglobin, and triglyceride values of such patients \[[@B30]\]. In an inception RA cohort, anti-TNF-*α* therapy was associated with a 51% reduction in the risk of DM \[[@B31]\]. One study reported that, among patients with RA, the multivariate adjusted ORs for DM were 0.62 (95% CI = 0.42-0.91) for anti-TNF-*α* therapy, 0.77 (95% CI = 0.53-1.13) for MTX, and 0.54 (95% CI = 0.36-0.80) for hydroxychloroquine compared with other nonbiological DMARDs \[[@B32]\].

Strengths of the study are that it was based on a large and representative population cohort, extracted from the NHI system covering 99% population in Taiwan, avoiding bias from selection, nonresponse, or poor recall. The NHIRD has been shown to have good levels of accuracy and completeness in recording prescriptions and clinical diagnoses. Besides, we not only adjusted for many potential confounding factors but also used the propensity score matching to select general patients as the control group. Therefore, the study indicates that RA patients increase of 1.31 times the risk of CVD, with a narrower and statistically significant confidence interval.

There are a few limitations in the study. NHRID do not contain patients\' biochemical test data. However, in order to avoid miscoding problems, we use the ICD-9-CM code of RA and antirheumatic drugs to select RA patients to improve diagnostic accuracy. In addition, some factors affecting the CVD cannot be obtained from the NHI database. For example, life-related variables from these patients cannot be included in the analysis, such as BMI, alcohol consumption, and tobacco consumption behavior. Moreover, the medications, such as NSAIDs and corticosteroids, may increase the risk of CVD. The medication is the confounding factor really extremely to control, especially in the retrospective cohort study. Each patient in the study period may receive inconsistent prescription patterns in the follow-up period, including drug type, drug dose, and medication duration. Therefore, our study reduced the medication confounding by adjusted comorbidity disease. This study was a nationwide population-based study. Thus, the study results have the accuracy and representativeness, although without the medication status. However, this study can only provide evidence to prove the association between RA and CVD, which cannot represent the cause-effect relation. It is necessary to obtain this information from other databases or questionnaires to analyze its influence on their relationship in future research.

5. Conclusions {#sec5}
==============

The proportion of NSAID prescriptions was highest in Taiwan. The study highlights the significant increase in the risk of developing CVD in patients with RA. The study further corroborated this relationship via the Cox proportional hazard model. HTN, DM, and CKD were related to incident CVD. Furthermore, age is the greatest risk factors contributing to the occurrence of incident CVD.
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###### 

The characteristics of RA and general patients (matched in 1:5 scales).

  Variables                            General patients   RA patients     Total           p-value ^1^                     
  ------------------------------------ ------------------ --------------- --------------- ------------- -------- -------- --------
    Total                              76,830             100             15,366          100           92,196   100       
  Gender                                                                                                                  \>0.99
   Male                                24,515             319.91          4,903           31.91         29,418   31.91     
   Female                              52,315             68.09           10,463          68.09         62,778   68.09     
  Age (year)                           49.26 ± 17.07      50.01 ± 16.02   49.39 ± 16.90   \>0.99                          
   ≦34                                 12,985             16.9            2,597           16.9          15,582   16.9      
   35-44                               13,400             17.44           2,680           17.44         16,080   17.44     
   45-54                               20,860             27.15           4,172           27.15         25,032   27.15     
   55-64                               14,698             19.13           2,939           19.13         17,637   19.13     
   ≧65                                 14,887             19.38           2,978           19.38         17,865   19.38     
  Premium-based Monthly income (NTD)                                                                             \>0.99   
   Insured dependent                   20,015             26.05           4,003           26.05         24018    26.05     
   \<17,280                            12,865             16.74           2,573           16.74         15438    16.74     
   17,281\~22,800                      23,763             30.93           4,752           30.93         28515    30.93     
   ≧22,801                             20,187             26.27           4,038           26.27         24225    26.27     
  Urbanization                                                                                                            \>0.99
   Level 1                             22,753             29.61           4,550           29.61         27,303   29.61     
   Level 2                             24,450             31.82           4,890           31.82         29,340   31.82     
   Level 3                             12,156             15.82           2,431           15.82         14,587   15.82     
   Level 4                             10,655             13.87           2,131           13.87         12,786   13.87     
   Level 5                             1,377              1.79            276             1.79          1,653    1.79      
   Level 6                             2,605              3.39            521             3.39          3,126    3.39      
   Level 7                             2,834              3.69            567             3.69          3,401    3.69     

^1^Used Chi-square test to exam the characteristics distribution.

###### 

Covariates associated with CVD with univariate analysis.

  Variable     Without CVD     With CVD        Total   p-value ^1^                      
  ------------ --------------- --------------- ------- ------------- --------- -------- ---------
    Total      85,531          100             6,665   100           92,196    100.00    
  Patients                                                                              \<0.001
   General     71,480          93.04           5,350   6.96          76,830    83.33     
   RA          14,051          91.44           1315    8.56          15,366    16.67     
  Gender                                                                                \<0.001
   Male        26,996          91.77           2,422   8.23          29,418    31.91     
   Female      58,535          93.24           4,243   6.76          62,778    68.09     
  Age (year)   48.19 ± 16.60   64.85 ± 12.43                         \<0.001            
   ≦34         15,508          99.53           74      0.47          15,582    16.9      
   35-44       15,806          98.30           274     1.70          16,080    17.44     
   45-54       23,996          95.86           1036    4.14          25,032    27.15     
   55-64       16,076          91.15           1561    8.85          17,637    19.13     
   ≧65         14,145          79.18           3720    20.82         17,865    19.38     
  HTN                                                                                   \<0.001
   No          77,886          93.40           5,504   6.60          83,390    90.45     
   Yes         7,645           86.82           1,161   13.18         8,806     9.55      
  HPL                                                                                   \<0.001
   No          85,220          92.80           6,611   7.20          91,831    99.6      
   Yes         311             85.21           54      14.79         365       0.4       
  MS                                                                                    0.176
   No          85,408          92.78           6,651   7.22          92,059    99.85     
   Yes         123             89.78           14      10.22         137       0.15      
  DM                                                                                    \<0.001
   No          79,705          93.67           5,385   6.33          85,090    92.29     
   Yes         5,826           81.99           1280    18.01         7,106     7.71      
  CKD                                                                                   \<0.001
   No          84,243          92.97           6,366   7.03          90,609    98.28     
   Yes         1,288           81.16           299     18.84         1,587     1.72      

^1^Used Chi-square test to exam the characteristics distribution.

^2^RA, rheumatoid arthritis; HTN, hypertension; HPL, hyperlipidemia; MS, metabolic syndrome; DM, diabetes mellitus; CKD, chronic kidney disease.

###### 

Risk of CVD in RA patients with multivariable analysis of Cox regression analysis.

  Variables         Unadjusted   95% CI        p-value   Adjusted   95% CI        p-value
  ----------------- ------------ ------------- --------- ---------- ------------- ---------
  Patients                                                                         
   General (ref.)   1                                    1                         
   RA               1.36         1.28-1.45     \<0.001   1.31       1.23-1.39     \<0.001
  Gender                                                                           
   Male (ref.)      1                                    1                         
   Female           0.83         0.79-0.87     \<0.001   0.82       0.78-0.86     \<0.001
  Age (year)                                                                       
   ≦34 (ref.)       1                                    1                         
   35-44            3.56         2.75-4.60     \<0.001   3.50       2.71-4.53     \<0.001
   45-54            9.11         7.20-11.54    \<0.001   8.56       6.76-10.83    \<0.001
   55-64            20.62        16.33-26.03   \<0.001   17.65      13.97-22.31   \<0.001
   ≧65              52.41        41.64-65.97   \<0.001   40.32      31.99-50.84   \<0.001
  HTN                                                                              
   No (ref.)        1                                    1                         
   Yes              3.75         3.57-3.94     \<0.001   1.57       1.48-1.65     \<0.001
  HPL                                                                              
   No (ref.)        1                                    1                         
   Yes              2.29         2.15-2.44     \<0.001   0.99       0.93-1.07     0.963
  MS                                                                               
   No (ref.)        1                                    1                         
   Yes              1.58         0.94-2.67     0.086     0.91       0.54-1.53     0.717
  DM                                                                               
   No (ref.)        1                                    1                         
   Yes              3.24         3.04-3.44     \<0.001   1.47       1.38-1.57     \<0.001
  CKD                                                                              
   No (ref.)        1                                    1                         
   Yes              2.93         2.61-3.29     \<0.001   1.48       1.31-1.66     \<0.001

RA, rheumatoid arthritis; HTN, hypertension; HPL, hyperlipidemia; MS, metabolic syndrome; DM, diabetes mellitus; CKD, chronic kidney disease.

[^1]: Academic Editor: Lorenzo Cavagna
